메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules

WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. WuXia293Stable platform maintains stable expression and consistent product quality during long-term cell passages, enabling scalable clinical and commercial manufacturing. SHANGHAI, Aug. 11, 2025 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293Stable, a new platform designed for the developm
- 김갑성 기자
- 2025-08-11 16:30
Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

HONG KONG, Aug. 11, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ivonescimab, a first-in-class PD-1/VEGF bispecific antibody developed by Akeso, in small cell lung cancer (SCLC). This study is designed to assess the efficacy and safety of ivonescimab as consolidation therapy in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced progression following standard concurrent chemoradiotherapy
- 김갑성 기자
- 2025-08-11 10:52
Philippines' AC Health partners with Singapore's ABC Impact in vision to transform health for every Filipino

MANILA, Philippines, Aug. 11, 2025 -- AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the Singapore-based impact investor dedicated to Asia and backed by Temasek Trust and Temasek. This strategic investment marks ABC Impact's entry into the Philippine healthcare sector, expanding its regional footprint. Under the agreement, ABC Impact will infuse primary capital for a c.16% minority stake in AC Health. The investment will support AC Health's vision of transforming healthcare for every Filipino by building a se
- 김갑성 기자
- 2025-08-11 10:31
HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 11, 2025 -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™ Plus, its second Laboratory Developed Test (LDT) available in the United States. Building on the foundation of FibroSIGHT™[1], which debuted just months earlier, FibroSIGHT™ Plus introduces an additional feature of automated quantitative analysis of fibrosis - a key advancement that enables more consistent and precise characterization at diagnosis and tracking of fibrosis in patients with Metabolic Dysfunction-associated Steatohepatitis
- 김갑성 기자
- 2025-08-11 09:00
Brain Navi Biotechnology's NaoTrac performs first surgeries in Spain

Brain Navi has officially landed in Spain! TAIPEI, Aug. 11, 2025 -- Such an achievement has been made possible through the first of many collaborations with our valued partner, Palex Healthcare. This milestone has been reached not only thanks to Palex's solid reputation and deep experience in the Spanish medical market, but also due to the trust and commitment of their team. Brain Navi CEO Jerry Chen stated, "Brain Navi is proud to work alongside a partner that shares our vision of surgical innovation and desire to improve the well-being of patients continuously."&nbs
- 김갑성 기자
- 2025-08-11 09:00
Hugel launches botulinum toxin Letybo in Malaysia

- The company strengthens brand experience for local medical professionals through academic events and hands-on workshops - It will solidify the market position of premium toxin products through Malaysian partner Venusys Medical SEOUL, South Korea, Aug. 11, 2025 -- Hugel Inc., a leading global medical aesthetics company chaired by Suk Cha, has officially launched its botulinum toxin product Letybo in Malaysia – an emerging market for medical aesthetics in Southeast Asia. The company's Malaysian partner Venusys Medical Sdn Bhd introduced Letybo at the
- 김갑성 기자
- 2025-08-11 08:30
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

[ 메디채널 김갑성 기자 ] Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 9, 2025 -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible diagnostic tool at the point of care. As cases continue to rise across tropical and subtropical regions, timely detection and differentiation from other arboviral
- 김갑성 기자
- 2025-08-09 09:30
GenScript Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology

PISCATAWAY, N.J., Aug. 8, 2025 -- GenScript Biotech Corporation (HK.1548), a global leader in life sciences innovation, today unveiled its new global brand platform: Scripting Possibilities—a future-forward identity designed to match the speed, complexity, and promise of modern biotechnology. The brand relaunch reflects GenScript's ambition to become the most trusted partner for researchers worldwide—delivering scientific accelerations from discovery to manufacturing with speed, precision, and purpose. The new platform, visual identity, and tagline roll out globally today, on GenScript
- 김갑성 기자
- 2025-08-08 20:30
Career-switching professionals, twins and trailblazers: Duke-NUS' Class of 2029 redefines path to medicine

[ 메디채널 김갑성 기자 ] 78 students embark on their journey to become doctors at Duke-NUS Medical School's 19th White Coat Ceremony 46 individuals have made the shift from other careers into medicine, including a lawyer with experience as a yoga coach, a software engineer and professionals from diverse paths, underscoring Duke-NUS' distinct positioning as Singapore's only graduate-entry medical school For the first time, twin sisters enter the MD programme together SINGAPORE, Aug. 8, 2025 -- A new chapter in Singapore's healthcare story began today as 78 aspiring doctors from Duke-NUS
- 김갑성 기자
- 2025-08-08 19:51
RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA

YANTAI, China, Aug. 8, 2025 -- On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed bispecific antibody, RC148, for the treatment of multiple advanced malignant solid tumors in the US. RC148 is a PD-1 and VEGF-targeting bispecific antibody, an innovative molecule developed by RemeGen using its bispecific antibody technology platform. Currently, the clinical trials of RC148 as monotherapy and combination therapy for the treatmen
- 김갑성 기자
- 2025-08-08 17:50

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-09-05_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 05일 15시 40분